© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Targeting KRAS Mutations in Advanced NSCLC
May 27, 2020
Shared insight on recent advances in KRAS-mutant NSCLC, with a focus on new therapies on the horizon.
Addressing the Mechanism of Action for the AKT Pathway in TNBC
May 26, 2020
Rebecca Dent, MD, discusses how investigators are targeting pathways in patients with triple negative breast cancer.
FDA Approves Frontline Nivolumab/Ipilimumab/Chemo for Advanced NSCLC
May 26, 2020
Nivolumab plus ipilimumab in combination with chemotherapy was granted accelerated approval for the frontline treatment of patients with metastatic or recurrent non–small cell lung cancer who do not harbor EGFR or ALK genomic tumor abberations.
Entinostat Combo Fails to Meet End Point in Phase 3 HR+/HER2– Breast Cancer Study
May 26, 2020
Entinostat plus exemestame did not improve overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.
Matous Evaluates Treatment Strategies for Transplant-Ineligible Multiple Myeloma
May 26, 2020
Jeffrey Matous, MD, discussed strategies for treating a 51-year-old male patients with transplant-ineligible multiple myeloma, during a live Targeted Oncology case-based peer perspectives conversation with other experts.
Bettering Survival With Telaglenastat Combinations in RCC
May 26, 2020
In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD, provided background on the phase 2 ENTRATA study and discussed the next steps with telaglenastat in the RCC treatment landscape.
FDA Grants Fast Track Designation to Novel Small Molecule Drug in LPL and WM
May 26, 2020
"Fast Track Designation for lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia further supports our clinical development strategy to quickly and efficiently provide these patients with an effective therapeutic alternative."
Sacituzumab Govitecan Brings Long-Awaited Progress in the Treatment Landscape of mTNBC
May 25, 2020
In an interview with Targeted Oncology following the announcement of sacituzumab govitecan accelerated FDA approval, Hope Rugo, MD, discussed the published data from the phase 1/2 basket trial and the relevance of having sacituzumab govitecan available for the treatment of patients with metastatic triple negative breast cancer.
Assay Shows Value for Patients With Low-Risk Prostate Cancer
May 25, 2020
Aaron E. Katz, MD, discusses a genomic test for patients with low-risk prostate cancer.
With Patients’ Safety Top of Mind, Oncologists Develop Innovative Care Plans During Pandemic
May 25, 2020
"Our efforts in the cancer clinic have been driven by patient safety and also maintaining patient access to care. In the age of COVID-19, those 2 things are sometimes at odds with each other."